Literature DB >> 222800

Comparison of indirect hemagglutination and indirect immunofluorescence tests with microneutralization tests for detection of type-specific Herpesvirus hominis antibody.

L D Johnson, D A Fuccillo, H Stalder, M A Oxman, C E Fraser, D L Madden.   

Abstract

Indirect hemagglutinating and immunofluorescent antibody responses to Herpesvirus hominis types 1 and 2 were compared to neutralizing antibody responses in infected humans from whom H. hominis type 1 or 2 was isolated. The indirect immunofluorescent antibody test was shown to be the most sensitive and specific for primary human infections. The sensitivity and specificity of the indirect hemagglutination and the immunofluorescent antibody tests were shown to be equal to that of the microneutralization test among patients who had primary or recurrent H. hominis type 2 infections. It is suggested that the indirect hemagglutination test is preferable for assaying large populations for previous infection with H. hominis type 2 because it is rapid, easier to perform, and more economical. The intermediate range of titer differences (deltat) between H. hominis types 1 and 2 previously reported to be due to infections with both viruses was shown to occur in all three tests among patients with primary infections with either virus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222800      PMCID: PMC273035          DOI: 10.1128/jcm.9.3.384-390.1979

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  A review of the identification and titration of antibodies to herpes simplex viruses type 1 and type 2 in human sera.

Authors:  G Plummer
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

2.  Use of the 51 Cr release test to demonstrate patterns of antibody response in humans to herpesvirus types 1 and 2.

Authors:  J W Smith; E Adam; J L Melnick; W E Rawls
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

3.  Type-specific surface antigens of cells infected with herpes simplex virus (1 and 2).

Authors:  A J Nahmias; I DelBuono; K E Schneweis; D S Gordon; D Thies
Journal:  Proc Soc Exp Biol Med       Date:  1971-10

4.  Differentiation between type 1 and type 2 strains of herpes simplex virus by an indirect immunofluorescent technique.

Authors:  L Geder; G R Skinner
Journal:  J Gen Virol       Date:  1971-08       Impact factor: 3.891

5.  Fluorescent antibody studies on herpesviruses from new-world primates.

Authors:  C E Fraser; L V Meléndez; M D Daniel; H H Barahona
Journal:  J Natl Cancer Inst       Date:  1972-07       Impact factor: 13.506

6.  Typing Herpesvirus hominis antibodies and isolates by inhibition of the indirect hemagglutination reaction.

Authors:  A F Back; N J Schmidt
Journal:  Appl Microbiol       Date:  1974-09

7.  Herpesvirus antibody and carcinoma in situ of the cervix.

Authors:  L W Catalano; L D Johnson
Journal:  JAMA       Date:  1971-07-26       Impact factor: 56.272

8.  Herpes simplex virus and cancer of the cervix.

Authors:  G Plummer; J G Masterson
Journal:  Am J Obstet Gynecol       Date:  1971-09       Impact factor: 8.661

9.  The association of herpesvirus type 2 and carcinoma of the uterine cervix.

Authors:  W E Rawls; W A Tompkins; J L Melnick
Journal:  Am J Epidemiol       Date:  1969-05       Impact factor: 4.897

10.  Indirect hemagglutinating antibody response to Herpesvirus hominis types 1 and 2 in immunized laboratory animals and in natural infections of man.

Authors:  A F Back; N J Schmidt
Journal:  Appl Microbiol       Date:  1974-09
View more
  2 in total

1.  Comparison of indirect hemagglutination and 51chromium release tests for detection of Herpes Simplex Virus type 1 and 2 antibodies in patients with recurrent Herpes infections.

Authors:  L Kesavalu; P Seth
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

2.  Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody.

Authors:  A M Arvin; C M Koropchak; A S Yeager; L Pereira
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.